CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...

Q1 2025 Management View CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% ...

AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a large-scale multimodal deep learning model designed to accelerate cancer drug discovery. The companies say the ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology.

Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI.

After all, shares of Tempus AI, a healthcare-oriented artificial ... It recently announced an expanded partnership with AstraZeneca (NASDAQ: AZN) to discover new drug targets, among other things.

Tempus AI delivered a record quarter, supported by strong revenue growth across its segments and a landmark $200 million agreement with AstraZeneca and Pathos. The company raised its full-year ...